-
RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study
•
China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products Administration (NMPA) to initiate an open, single-center Phase Ib/II clinical study. The study will assess the safety, efficacy, and pharmacokinetics of its antibody-drug conjugate (ADC) candidate RC48 (disitamab vedotin) combined with Hengrui pharmamceuticals’ pyrotinib, a…
-
Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine SCB-2019 (CpG 1018/Alum) in Zhejiang. This recombinant protein vaccine is recommended by the national second dosage (fourth shot) booster immunization plan and is suitable for use in the elderly, immune-compromised individuals, and populations with complications.…
-
CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus Pharmaceuticals Inc. The deal pertains to CSPC’s anti-nectin-4 antibody drug conjugate (ADC) SYS6002. Under the terms of the agreement, Corbus obtains development and commercialization rights to SYS6002 in the United States, EU, United Kingdom, Canada,…
-
Mingche Biotechnology Secures Pre-Series A Funding for Medical Device Innovation
•
China-based high-value medical device firm Mingche Biotechnology (Suzhou) Co., Ltd has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. This significant capital raise was led by Suzhou Industrial Park Development Zhidao Equity Investment Partnership and Qianrong Capital, with additional contributions from Haida Investment. The funds…
-
Dessight Biomedical Secures Pre-Series A Funding for Ophthalmic Innovations
•
Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. This significant capital injection was led by Linear Venture, with GL Ventures also participating. The funds will be directed towards market filing for an ophthalmic surgery robot, the development of microsurgery robots, and…
-
Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody
•
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase I clinical study for its BA1106, an in-house developed CD25 monoclonal antibody (mAb). The study, filed by subsidiary Shandong BoAn Biotechnology Co., Ltd, is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of…
-
Zelgen’s ZGGS15 Accepted for NMPA Review as First Global BsAb Filing
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for its ZGGS15, a bispecific antibody (BsAb) targeting LAG-3 and TIGIT in advanced solid tumors, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone as ZGGS15 is touted…
-
Kintor’s GT20029 Shows Positive Results in US Phase I Study for AGA and Acne
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive topline data from a Phase I clinical study in the United States for its GT20029, a treatment for androgenetic alopecia (AGA) and acne. This marks a significant step in the development of a novel treatment option for these common conditions. Phase…
